All In Biotech

Drug Trial Radar · NCT05365178

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

A Randomized, Double-blind, Parallel-controlled Phase III Trial Evaluating the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated HR-positive, HER2-negative Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

432

Actual

Start

Jul 1, 2022

Primary completion

Jul 2, 2025

Study completion Jun 2026

Sponsor

Sponsor type
Industry
First posted
May 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, parallel-controlled, multicenter trial design was used in this study. Subjects who meet the criteria will be randomly divided into 2:1 groups to receive TBQ3616 capsule combined with Fulvestrant injection (experimental group) or placebo capsule combined with fulvestrant (control group). A total of 428 subjects were required.

Conditions

  • HR-positive, HER2-negative Breast Neoplasms

Interventions

  • TQB3616 capsuleDrug

    TQB3616 capsule is a CDK (cyclin-dependent kinases) 2/4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK2/4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase

  • PlaceboDrug

    It is a placebo

  • Fulvestrant injectionDrug

    Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival as assessed by the investigatorTime frame: Baseline up to progressive disease (PD)/die, about 25.8 months

Locations

88 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The Southwest Hospital of AMU

    Chongqing, Chongqing Municipality, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Nanfang Hospital Southern Medical University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Jieyang People's Hospital

    Jieyang, Guangdong, China

  • Maoming people's hospital

    Maoming, Guangdong, China

  • Yue Bei People's Hospital

    Shaoguan, Guangdong, China

  • ShenZhen People's Hospital

    Shenzhen, Guangdong, China

  • PeKing University ShenZhen Hosipital

    Shenzhen, Guangdong, China

  • Zhongshan City People's Hospital

    Zhongshan, Guangdong, China

  • The Fifth Affiliated Hospital of Sun Yat-Sen University

    Zhuhai, Guangdong, China

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Yulin First People's Hospital

    Yulin, Guangxi, China

  • The Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • Hebei Cangzhou Hospital of Integrated Traditional Chinese

    Cangzhou, Hebei, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Jiamusi Cancer Hospital

    Jiamusi, Heilongjiang, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Yichang Central People's Hospital

    Yichang, Hubei, China

  • The First People's Hospital of Changde

    Changde, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.